# Acute Rosuvastatin for Preventing Myocardial Damage in Patients With ACS

Study · id `cardio:ct-nct01245803` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01245803](<https://clinicaltrials.gov/study/NCT01245803>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01245803

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 400 participants.

## Technical summary

Registry record NCT01245803. Randomized; single masking; primary purpose treatment. Start 2010-04 (registry gives no type); primary completion 2011-04 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 400 participants (planned count; ClinicalTrials.gov record NCT01245803, source copy `cardio:ctgov-nct01245803-2010-11-23`, retrieved 2026-10-31)
- Start date: 2010-04 (registry gives no type) (ClinicalTrials.gov record NCT01245803, source copy `cardio:ctgov-nct01245803-2010-11-23`, retrieved 2026-10-31)
- Primary completion: 2011-04 (anticipated) (ClinicalTrials.gov record NCT01245803, source copy `cardio:ctgov-nct01245803-2010-11-23`, retrieved 2026-10-31)
- Completion: 2011-05 (anticipated) (ClinicalTrials.gov record NCT01245803, source copy `cardio:ctgov-nct01245803-2010-11-23`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT01245803, source copy `cardio:ctgov-nct01245803-2010-11-23`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01245803-2010-11-23`, retrieved 2026-10-31)

## The registry's words

- Brief title: Acute Rosuvastatin for Preventing Myocardial Damage in Patients With ACS
- Acronym: AVATAR
- Condition: Acute Coronary Syndrome
- Condition: Angioplasty
- Intervention (Drug): additional rosuvastatin loading
- Intervention (Drug): placebo control
- Lead sponsor: Beijing Anzhen Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry lists this organization as the lead sponsor: Beijing Anzhen Hospital (`cardio:org-beijing-anzhen-hospital`)

## Provenance

Content hash: b6afe02a1f038faad766d4ccec8c449b5ebf889b7f627e39142f4df225b9b1ca
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
